⚕ GalenOps field
←

SITE003-0242

completed

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE003 (CAN) · Dr. Okafor
consented 2022-12-12

AEs
5
Serious
0
Dropout signal
–

Adverse events

mild assessed

Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-04-23 (study day 123); relationship: not assessed

moderate assessed

Grade 2 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2023-08-14 (study day 236); relationship: Y

mild assessed

Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-12-06 (study day 350); relationship: Y

moderate assessed

Grade 2 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2024-01-13 (study day 388); relationship: not assessed

moderate assessed

Grade 2 Fatigue — outcome: RECOVERED/RESOLVED; onset 2024-01-25 (study day 400); relationship: not assessed

Data queries

No data queries.